PPLPHARMA Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,270 Cr
verified against source
Revenue YoY
17%
reported change
EBITDA
₹285 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Piramal Pharma delivered a strong Q1 FY27 with 17% YoY revenue growth to Rs 2,270 crore and EBITDA expansion of 400bps to 12%, translating to 72% EBITDA growth. All three business segments—CDMO (19% growth), Complex Hospital Generics (17% growth), and Consumer Healthcare (mid-teen growth)—contributed uniformly. The CDMO business saw broad-based demand recovery with improved RFP activity directed at higher-margin overseas sites; the Riverview ADC facility is now commercial. Complex Hospital Generics benefited from ex-US market gains and market share expansion in sevoflurane (48% US share). Consumer Healthcare showed robust power brand momentum (23% growth, 53% of sales) and e-commerce acceleration (40% growth, 28% of sales). Management maintained annual guidance while confirming $21 million Q1 capex spend against a $120-135 million full-year budget. Tax rate will remain elevated this year due to overseas facility scaling but normalize to 24-25% by FY30 when targeting 25% EBITDA margins. Key risks include Chinese competition in generics, customer decision timeline extensions, and geopolitical tariff uncertainties affecting supply chains.
Colored figures show movement against the previous available record.
Guidance to track
- Full-year capex guidance maintained at $120-135 million, with $21 million already spent in Q1. Lexington sterile injectable expansion remains on track for calendar year 2027 completion.
- Management maintained original annual guidance for revenue growth and profitability across all three business segments despite strong Q1 performance, citing early stage of fiscal year.
- Company targets 25% EBITDA margins by FY30, primarily driven by CDMO business operating leverage as overseas facility utilization scales up and differentiated offerings mix improves.
- Effective tax rate appears elevated currently due to overseas facilities not yet at scale. Normalized rate should reach 24-25% once operations scale, with reduction phased by jurisdiction.
Risks flagged
- Canalog supplies expected from Q2 FY27—an important growth driver for Complex Hospital Generics—but timing and magnitude of contribution remains uncertain pending execution. Management deflected questions on organic growth sustainability beyond Q1.
- Chinese competitive pressures in intrathecal and other hospital generic products persist despite management actions taken last year. Analysts questioned whether Q1's strong 17% growth (particularly ex-US) represents sustainable trend or one-time market share recovery.
- Piramal does not anticipate any revenue from the large innovator contract with inventory destocking issues this fiscal year (FY27), with potential recovery pushed to FY28. Management declined to provide specific customer or product details, limiting visibility.
- Analyst raised concerns about potential 25% tariffs on India and 100% tariffs on generics affecting SEO florine supply chain, though API and final drug product manufacturing in Bethlehem, Pennsylvania provides partial mitigation.
Key quotes
- We don't currently anticipate anything this fiscal year. We think we communicated that was the expectation last quarter and we will continue to be in touch with them because we've served them on other projects and when their situation changes in a material manner we would likely let you all know.
- We are seeing encouraging signs of recovery in US biopharma funding... Combined with the continued recovery in US biopharma funding over the last few quarters, these initiatives have contributed to a meaningful increase in RFP activity across most of our sites.
- We are expecting that increased utilization will help us to get scale and get operating leverage which will help us to break even. I think this quarter you will have seen that increase in revenue in the overseas subsidiaries which has helped improve our EBITDA margin.
Research modules